vs
Side-by-side financial comparison of NATURES SUNSHINE PRODUCTS INC (NATR) and OFG BANCORP (OFG). Click either name above to swap in a different company.
OFG BANCORP is the larger business by last-quarter revenue ($184.3M vs $123.8M, roughly 1.5× NATURES SUNSHINE PRODUCTS INC). OFG BANCORP runs the higher net margin — 30.3% vs 3.3%, a 27.0% gap on every dollar of revenue. On growth, NATURES SUNSHINE PRODUCTS INC posted the faster year-over-year revenue change (4.7% vs 0.9%). OFG BANCORP produced more free cash flow last quarter ($199.3M vs $7.6M). Over the past eight quarters, NATURES SUNSHINE PRODUCTS INC's revenue compounded faster (5.6% CAGR vs 2.8%).
Nature's Sunshine Products, Inc. also known as "NSP", is a manufacturer of dietary supplements, including herbs, vitamins, minerals, and personal care products. It is based in Lehi, Utah, with a manufacturing facility in Spanish Fork, Utah.
OFG Bancorp, founded in 1964, is the financial holding company for Oriental Bank, located in San Juan, Puerto Rico. OFG offers a wide range of retail and commercial banking, lending and wealth management products, services and technology, primarily in Puerto Rico and the U.S. Virgin Islands through its principal subsidiaries: Oriental Bank, Oriental Financial Services LLC, and Oriental Insurance LLC. Its headquarters are located at Oriental Center, 254 Muñoz Rivera Avenue, San Juan, PR 00918....
NATR vs OFG — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $123.8M | $184.3M |
| Net Profit | $4.1M | $55.9M |
| Gross Margin | 72.5% | — |
| Operating Margin | 4.3% | 25.7% |
| Net Margin | 3.3% | 30.3% |
| Revenue YoY | 4.7% | 0.9% |
| Net Profit YoY | 1379.4% | 11.0% |
| EPS (diluted) | $0.23 | $1.27 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $123.8M | $184.3M | ||
| Q3 25 | $128.3M | $186.2M | ||
| Q2 25 | $114.8M | $182.4M | ||
| Q1 25 | $113.2M | $178.6M | ||
| Q4 24 | $118.2M | $182.7M | ||
| Q3 24 | $114.6M | $174.7M | ||
| Q2 24 | $110.6M | $179.8M | ||
| Q1 24 | $111.0M | $174.4M |
| Q4 25 | $4.1M | $55.9M | ||
| Q3 25 | $5.3M | $51.8M | ||
| Q2 25 | $5.3M | $51.8M | ||
| Q1 25 | $4.7M | $45.6M | ||
| Q4 24 | $-321.0K | $50.3M | ||
| Q3 24 | $4.3M | $47.0M | ||
| Q2 24 | $1.3M | $51.1M | ||
| Q1 24 | $2.3M | $49.7M |
| Q4 25 | 72.5% | — | ||
| Q3 25 | 73.3% | — | ||
| Q2 25 | 71.7% | — | ||
| Q1 25 | 72.1% | — | ||
| Q4 24 | 72.0% | — | ||
| Q3 24 | 71.3% | — | ||
| Q2 24 | 71.4% | — | ||
| Q1 24 | 71.2% | — |
| Q4 25 | 4.3% | 25.7% | ||
| Q3 25 | 7.0% | 33.0% | ||
| Q2 25 | 3.7% | 36.1% | ||
| Q1 25 | 5.4% | 33.3% | ||
| Q4 24 | 3.8% | 28.9% | ||
| Q3 24 | 4.6% | 35.4% | ||
| Q2 24 | 5.1% | 39.6% | ||
| Q1 24 | 4.2% | 38.9% |
| Q4 25 | 3.3% | 30.3% | ||
| Q3 25 | 4.2% | 27.8% | ||
| Q2 25 | 4.6% | 28.4% | ||
| Q1 25 | 4.2% | 25.5% | ||
| Q4 24 | -0.3% | 27.6% | ||
| Q3 24 | 3.8% | 26.9% | ||
| Q2 24 | 1.2% | 28.4% | ||
| Q1 24 | 2.1% | 28.5% |
| Q4 25 | $0.23 | $1.27 | ||
| Q3 25 | $0.30 | $1.16 | ||
| Q2 25 | $0.28 | $1.15 | ||
| Q1 25 | $0.25 | $1.00 | ||
| Q4 24 | $-0.02 | $1.10 | ||
| Q3 24 | $0.23 | $1.00 | ||
| Q2 24 | $0.07 | $1.08 | ||
| Q1 24 | $0.12 | $1.05 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $93.9M | $1.0B |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $161.6M | $1.4B |
| Total Assets | $261.1M | $12.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $93.9M | $1.0B | ||
| Q3 25 | $95.6M | $740.3M | ||
| Q2 25 | $81.3M | $851.8M | ||
| Q1 25 | $86.5M | $710.6M | ||
| Q4 24 | $84.7M | $591.1M | ||
| Q3 24 | $78.7M | $680.6M | ||
| Q2 24 | $68.7M | $740.4M | ||
| Q1 24 | $77.8M | $754.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $2.1M | — |
| Q4 25 | $161.6M | $1.4B | ||
| Q3 25 | $166.7M | $1.4B | ||
| Q2 25 | $163.7M | $1.3B | ||
| Q1 25 | $167.1M | $1.3B | ||
| Q4 24 | $161.0M | $1.3B | ||
| Q3 24 | $162.6M | $1.3B | ||
| Q2 24 | $156.4M | $1.2B | ||
| Q1 24 | $159.7M | $1.2B |
| Q4 25 | $261.1M | $12.5B | ||
| Q3 25 | $264.8M | $12.2B | ||
| Q2 25 | $254.9M | $12.2B | ||
| Q1 25 | $252.7M | $11.7B | ||
| Q4 24 | $240.9M | $11.5B | ||
| Q3 24 | $245.3M | $11.5B | ||
| Q2 24 | $235.8M | $11.3B | ||
| Q1 24 | $247.3M | $11.2B |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.01× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $9.9M | $217.7M |
| Free Cash FlowOCF − Capex | $7.6M | $199.3M |
| FCF MarginFCF / Revenue | 6.1% | 108.1% |
| Capex IntensityCapex / Revenue | 1.9% | 10.0% |
| Cash ConversionOCF / Net Profit | 2.41× | 3.90× |
| TTM Free Cash FlowTrailing 4 quarters | $28.8M | $345.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $9.9M | $217.7M | ||
| Q3 25 | $18.5M | $39.5M | ||
| Q2 25 | $4.3M | $35.9M | ||
| Q1 25 | $2.6M | $83.1M | ||
| Q4 24 | $12.2M | $252.5M | ||
| Q3 24 | $9.6M | $58.1M | ||
| Q2 24 | $1.3M | $95.1M | ||
| Q1 24 | $2.2M | $61.0M |
| Q4 25 | $7.6M | $199.3M | ||
| Q3 25 | $16.8M | $35.5M | ||
| Q2 25 | $3.0M | $31.8M | ||
| Q1 25 | $1.5M | $78.7M | ||
| Q4 24 | $10.0M | $231.2M | ||
| Q3 24 | $7.9M | $51.8M | ||
| Q2 24 | $-2.0M | $90.4M | ||
| Q1 24 | $-1.5M | $54.8M |
| Q4 25 | 6.1% | 108.1% | ||
| Q3 25 | 13.1% | 19.1% | ||
| Q2 25 | 2.6% | 17.4% | ||
| Q1 25 | 1.3% | 44.1% | ||
| Q4 24 | 8.5% | 126.5% | ||
| Q3 24 | 6.9% | 29.6% | ||
| Q2 24 | -1.9% | 50.3% | ||
| Q1 24 | -1.4% | 31.4% |
| Q4 25 | 1.9% | 10.0% | ||
| Q3 25 | 1.3% | 2.1% | ||
| Q2 25 | 1.2% | 2.3% | ||
| Q1 25 | 1.0% | 2.4% | ||
| Q4 24 | 1.9% | 11.7% | ||
| Q3 24 | 1.5% | 3.6% | ||
| Q2 24 | 3.0% | 2.6% | ||
| Q1 24 | 3.3% | 3.5% |
| Q4 25 | 2.41× | 3.90× | ||
| Q3 25 | 3.46× | 0.76× | ||
| Q2 25 | 0.81× | 0.69× | ||
| Q1 25 | 0.55× | 1.82× | ||
| Q4 24 | — | 5.02× | ||
| Q3 24 | 2.21× | 1.24× | ||
| Q2 24 | 0.97× | 1.86× | ||
| Q1 24 | 0.94× | 1.23× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NATR
| Other | $68.1M | 55% |
| General Health Products | $20.2M | 16% |
| Digestive Products | $13.8M | 11% |
| Cardiovascular Products | $12.1M | 10% |
| Personal Care Products | $4.4M | 4% |
| Immunity Products | $3.1M | 3% |
| Weight Management Products | $2.1M | 2% |
OFG
Segment breakdown not available.
